MedPath

investigation of probiotic effects on prophylaxis of pneumonia

Not Applicable
Recruiting
Conditions
Ventilator associated pneumonia(VAP).
Bacterial pneumonia, not elsewhere classified
Registration Number
IRCT20170704034901N2
Lead Sponsor
Birjand University of Medical Sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting
Sex
All
Target Recruitment
50
Inclusion Criteria

age over than 18 year
Length of stay in ICU for more than 5 days

Exclusion Criteria

Diarrhea at first visit or 48 hours before admission
immune deficiency
Regular treatment with probiotics before admission
pregnancy

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The incidence of ventilator associated pneumonia(VAP). Timepoint: Up to 15 days after starting probiotics, ventilator-associated pneumonia will be examined. Method of measurement: Daily hematologic examination (CBC and neutrophil count), active phase proteins (CRP or proxlotonin or ferritin) and chest X ray, Based on the American College of Chest Physicians clinical criteria, new or sustained infiltration in the CXR with 2 or 3 of the following findings: fever (.38.58C or ,35.08C), leukocytosis (white bloodcells . 10,000/mm3 or ,3,000/mm3), and purulent sputum.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath